K882 |
カタログ番号GC92554
One-Click Copy Product Info
|
K882 is an inhibitor of Src kinase.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
K882 is an inhibitor of Src kinase. It binds to Src (Kd = 315 nM), decreases phosphorylation at the tyrosine in position 416 (Y416), a Src activation site, and increases phosphorylation at Y527, an inactivation site. K882 reduces the proliferation of wild-type NCI H358 non-small cell lung cancer cells and NCI H358 cells expressing a KRASG12C mutation (IC50s = 2.14 and 2.03 µM, respectively). It also inhibits migration and invasion of NCI H358 cells when used at concentrations of 2, 4, and 8 µM, induces cell cycle arrest in the G2/M phase at 1, 4, and 8 µM, and induces apoptosis at 4 and 8 µM. K882 (25, 50, and 100 mg/kg) reduces tumor volume in an NCI H358 mouse xenograft model.
| Cas No. | SDF | ||
| Chemical Name | (E)-4-(2,5-dimethoxystyryl)quinazoline | ||
| Canonical SMILES | COC1=CC(/C=C/C2=NC=NC3=CC=CC=C23)=C(OC)C=C1 | ||
| Formula | C18H16N2O2 | M.Wt | 292.338 |
| 溶解度 | DMSO: Sparingly soluble: 1-10 mg/ml; Ethanol: Sparingly soluble: 1-10 mg/ml | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4207 mL | 17.1035 mL | 34.207 mL |
| 5 mM | 684.1 μL | 3.4207 mL | 6.8414 mL |
| 10 mM | 342.1 μL | 1.7103 mL | 3.4207 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)